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The effect of tamoxifen, a nonsteroidal antiestrogenic drug, on the in vitro growth of 
three cell lines derived from carcinoma of the uterine cervix (HeLa, CaSki, ME-180) was 
studied using the breast cancer cell line MCF-7 as a tamoxifen-sensitive control. Loga- 
rithmically growing cells were fed daily with medium containing 5% dextran-charcoal- 
treated fetal bovine serum (DS) and 0, I, 2.5, 5, 7.5, or 10 pM tamoxifen. The cell number 
in replicate cultures was assessed every other day by cell counts. Growth inhibition was 
expressed as the percentage of the cell number in control cultures fed with D5. At a 
concentration of 5 PLM tamoxifen, a clear decrease in cell proliferation, resulting in 66- 
74% inhibition of growth, was observed with MCF-7, HeLa, and ME-180 after 6 days of 
exposure to tamoxifen. Doses greater than 5 p,M resulted in cytotoxicity and progressive 
cell loss. With the CaSki cell line, 2.5 WM tamoxifen induced more than 60% growth 
inhibition and 5 pM tamoxifen was cytotoxic. Tamoxifen-induced growth inhibition was 
reversed by removing tamoxifen from the cell cultures, and the cells resumed logarithmic 
growth after a lag period of 24-48 hr. MCF-7, but not the cervical carcinoma, lines required 
estradiol for complete and rapid recovery of logarithmic growth. Our results indicate that 
tamoxifen inhibits cell growth of these cervical carcinoma cell lines by a mechanism 
different from that in MCF-7. 0 1988 Academtc PUSS, hc 
INTRODUCTION 
Since the initial finding of a growth inhibitory effect of antiestrogens in breast 
cancer tissue [l], the role of these agents in the treatment of malignant tumors 
arising from sex hormone-dependent tissues has been studied in numerous clinical 
and experimental studies. Currently, antiestrogens are widely used in breast 
cancer therapy [2-51, and more recently these agents have been suggested for 
therapy of endometrial [6-91 and ovarian cancer [lO,ll] as well. Carcinoma of 
the uterine cervix is the third most common gynecological cancer in the United 
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States, with an incidence of 8.9 cases/ 100,000 [ 121. Surgery and radiation therapy 
are effective treatment modalities for localized disease, but for patients with 
disseminated cancer, chemotherapy must be used. The uterine cervix is a part 
of the hormonally regulated female genital tract, and reports of hormonal therapy 
of cervical carcinoma using progesterone [ 131 or bromocriptine [ 141 have been 
published, but to our knowledge there are no studies dealing with the effects of 
the antiestrogenic agent tamoxifen on carcinoma of the uterine cervix. To determine 
the direct effects of tamoxifen on cervical cancer cells, the CaSki [1.5] ME-180 
1161, and HeLa [17] cell lines were compared to the breast cancer cell line MCF- 
7 [IS] in growth experiments in vitro. MCF-7 is frequently used for studying the 
effects of antiestrogenic agents on growth of malignant cells in vitro [19-221 and 
was therefore chosen to be used as an internal positive control. 
MATERIALS AND METHODS 
MCF-7 is a cloned cell line that was derived from a malignant pleural effusion 
of a female patient with metastatic breast cancer in 1973 by Soule et al. [18]. It 
was obtained at passage 185 for use in our laboratory in 1981 from Dr. C. McGrath 
of the Michigan Cancer Foundation, Detroit, Michigan. MCF-7 has been shown 
to contain cytosolic estrogen, progesterone, and androgen receptors [23,24]. The 
ME-180 cell line was established in 1970 by Sykes et al. [16]. The CaSki cell 
line was established by Patillo et al. in 1974 [15] and was obtained at passage 
518 from Dr. Robert Hussa in 1985. Both cell lines were derived from metastases 
to the bowel mesentery in patients with disseminated squamous cell carcinoma 
of the uterine cervix. In other studies we have shown that squamous cell carcinomas 
express a specific membrane antigen phenotype [25-271. ME-180 and CaSki both 
express this typical phenotype (unpublished data). The HeLa cell line was es- 
tablished by Gey et al. in 1952 [I71 from a biopsy of a primary tumor of the 
uterine cervix. This was an aggressive tumor as judged by the patient’s clinical 
course and is most likely an adenocarcinoma, according to a retrospective review 
of the histology slides published by Jones nearly 20 years later [28]. In agreement 
with this possibility we found that HeLa like MCF-7 and other nonsquamous 
cancer lines does not express the squamous carcinoma membrane antigen phenotype 
[26], HeLa and ME-180 were obtained in 1978 from Dr. J. Fogh from the human 
tumor cell line bank at the Memorial Sloan-Kettering Cancer Center. The passage 
numbers in our laboratory are consecutive from the passage number listed by 
Fogh. However, we do not know if the passages by Fogh were since the lines 
were obtained at the Sloan-Kettering Laboratory or were from the time of 
establishment. HeLa was from a vial frozen in 1972 and labeled passage 3, and 
ME-180 was frozen before 1978, and marked passage 26. In this study, passages 
33 and 45 of ME-180 and passages 12 and 28 of HeLa were used. MCF-7 was 
used in passages 235 and 238 and CaSki was used in passages 525 and 535. 
Dextran-coated charcoal treatment of fetal bovine serum. Unconjugated steroid 
hormones were depleted from the fetal bovine serum (FBS) used to prepare the 
culture media with dextran-coated charcoal (DCC) [29]. DCC was prepared by 
combining 5.0 g of charcoal (Norit A) and 500 mg of dextran T-70 in 100 ml of 
0.14 M NaCl with continuous stirring for at least 24 hr at room temperature 
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(charcoal-dextran ratio 1O:l). The DCC suspension was incubated with the FBS 
in a ratio of 25 ml DCC to 500 ml FBS for 30 min at 50°C with continuous 
mixing. After incubation, the serum was clarified by centrifugation at 3000 rpm 
for 15 min. The treated serum supematant (DCC-FBS) was sterilized by filtration 
(0.22 pm) and was used at a concentration of 5% to supplement complete minimal 
essential medium (cMEM). Medium prepared in this way is referred to as D5. 
Cell growth experiments. The cell lines were fed and passaged for several 
weeks before the experiments with complete minimal essential medium supple- 
mented with 15% fetal bovine serum. cMEM consists of MEM containing 2 mJ4 
glutamine, 1% nonessential amino acids, penicillin (100 u/ml), and streptomycin 
(100 pg/ml). Phenol red was also present. The cells were harvested from culture 
flasks by trypsinization with trypsin-EDTA solution containing 315 u/ml of 
tryptic activity and 0.2 M EDTA. The cell suspensions were washed, resuspended 
in cMEM prepared with 5% DCC-FBS (DS), and counted. The cell density was 
adjusted to 2.5 x lo4 cells/ml in D5. Two milliliters of the cell suspension was 
delivered to each 35-mm well of multiple 6-well plates for the cell growth ex- 
periments. During plating the cell suspension was frequently and thoroughly 
mixed to ensure a uniform cell density in each well. For each cell line, cell 
counts of three random wells were performed during plating to confirm the 
uniformity of cell distribution and to establish the actual initial number of cells 
plated. Multiple 6-well plates were prepared to establish replicates for each drug 
concentration and time point studied. The plates were kept in the incubator at 
37°C in an air atmosphere containing 5% CO, and saturated with water vapor. 
The cells were plated and allowed to grow for 3 or 4 days to reach the 
logarithmic growth phase. Thereafter the medium and the drugs were replaced 
daily to ensure that nutrient depletion would not be a factor affecting cell growth 
and that fresh and effective drug was present each day during the entire experiment. 
Cell counts. Trypsinized cells were centrifugated at 1000 rpm for 10 min, 
resuspended in a known volume, and counted visually in hemacytometer chambers 
using trypan blue to assess viability. Cell counts from replicate wells were averaged 
and reported as cell number per 35-mm well. 
Drug preparation. Tamoxifen citrate (TAM), generously provided by Stuart 
Pharmaceuticals, Wilmington, Delaware and Huhtamaki Oy, Pharmaceuticals, 
Turku, Finland, was dissolved in 70% ethanol at 1000 times the highest final 
concentration and stored as “stock” solutions at 20°C until used. Estradiol (17- 
P-estradiol, E2) was dissolved in absolute ethanol and was diluted to the appropriate 
final concentration with culture medium. In drug-treated and control cultures the 
final concentration of ethanol was always less than 0.1%. Ethanol at 0.1% or 
less has been shown not to affect growth rate, viability, or saturation density of 
the cells over the duration of the experiments [30]. 
Growth Inhibition 
RESULTS 
The results of a dose-response experiment showing the growth inhibitory and 
cytotoxic effects of tamoxifen on the three cervical cell lines and MCF-7 are 
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FIG. 1 Tamoxifen dose-response. Dose-response curves of ME-180, HeLa, CaSki, and MCF-7 
cell lines to tamoxifen concentrations of 0 (0), 1 @I (0). 2.5 PALM (O), 5 @I (a), 7.5 PLM (O), and 
10 pM (m). The control cultures were fed with culture medium DS + ethanol as the drug solvent. 
Each data point is the average of three replicate wells. 
shown in Fig. 1. Since the cell lines have different growth rates, the growth 
inhibitory effect of 1, 2.5, and 5 PM tamoxifen is shown in Fig. 2 as a percentage 
of control and as a function of time of exposure to tamoxifen. From these figures 
it is apparent that MCF-7 has the lowest threshold dose (1 PM) for growth 
inhibition, which results in approximately 55% growth inhibition by 6 days of 
exposure. However, at higher concentrations of tamoxifen, CaSki is the most 
sensitive of the four cell lines to both the growth inhibitory and cytotoxic effects 
of the drug. At a concentration of 2.5 pM the threshold for tamoxifen-induced 
growth inhibition is reached for all the cell lines tested, but at this concentration 
the range of growth inhibition is wide (24-77%) (Fig.2). Thus by 6 days of 
exposure to 2.5 pM tamoxifen, the cell numbers of the cultures were reduced 
by 77% relative to control for CaSki, 65% for MCF-7, 49% for HeLa, and 24% 
for ME-180. With 5 pM tamoxifen comparable growth inhibition was seen in 
HeLa (66%), ME-180 (74%), and MCF-7 (72%) cultures, whereas progressive 
cell loss was observed with CaSki cultures at this tamoxifen concentration. At 
concentrations of 7.5 and 10 pM tamoxifen, progressive cell loss and rapid 
decreases in cell numbers were seen in all cell lines, although there were differences 
in the time of exposure necessary to cause the effect (Fig.1). 
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FIG. 2 Effect of tamoxifen on ME-180, HeLa, CaSki, and MCF-7 cell lines. The growth inhibitory 
effect of tamoxifen is given as a percentage of control (number of live cells in tamoxifen-treated 
cultures/number of live cells in control cultures x 100) for three tamoxifen concentrations: (A) I 
PM; (B) 2.5 FM; (C) 5 PM. Each data point represents the average of three replicate wells. CaSki 
(A), ME-180 (W), HeLa (@), MCF-7 (0). 
Reversal of Growth Inhibition at Cytostatic Tamoxifen Concentrations 
For each cell line a characteristic concentration of tamoxifen was found at 
which a nearly constant cell number could be maintained for several days. This 
cytostatic concentration was determined for each cell line and was used to 
examine the reversibility of the growth inhibition phenomenon. These concentrations 
were 3.5 and 5 @4, respectively, for CaSki and MCF-7 and 6.5 pM for HeLa 
and ME-180 (Fig.3). Tamoxifen exposure was begun after the cells were in 
logarithmic growth on either Day 3 or 4 and continued for 3 or 4 days until 
cytostasis was obtained. Reversal of the tamoxifen-induced growth inhibition 
was then studied under three different conditions, which were (1) removal of 
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FIG. 3 Reversal of the growth inhibitory effect of tamoxifen. Cultures of ME-180, HeLa, CaSki, 
and MCF-7 cell lines were fed for either 3 or 4 days with tamoxifen at a concentration that caused 
cytostasis of each cell line. The concentrations of tamoxifen used were 6.5 FM (A, T) for ME-180 
and HeLa, 3.5 @f (0, T) for CaSki, and 5 @4 (a) for MCF-7. Tamoxifen-containing medium was 
then removed and the cultures were fed with either D5 medium containing ethanol only (0, D5); 
D5 medium containing tamoxifen; D5 medium containing 0.1 FM l7-P-estradiol (0, E2); or D5 
medium containing both tamoxifen and 17-/3-estradiol (a). T+ E2) in which the tamoxifen concentrations 
were the same as those used to reach cytostasis and the estradiol was used at l/50 of respective 
tamoxifen concentration. 
tamoxifen and feeding with fresh medium alone; (2) removal of tamoxifen and 
feeding with medium containing 0.1 pM 17-p-estradiol; (3) replacement of the 
tamoxifen by medium containing both tamoxifen and 17-/3-estradiol. In the latter 
case the 17-P-estradiol was used at l/50 of the tamoxifen concentration. 
The results of these experiments are shown in Fig. 3. For ME-180 and HeLa 
removal of tamoxifen and feeding with D5 medium resulted in recovery of log- 
arithmic growth within 24 hr whereas the recovery of CaSki and MCF-7 under 
these conditions was slower and increases in cell number were not apparent until 
48 hr after removal of the tamoxifen. However, the tamoxifen-induced growth 
inhibition was reversible in all four cell lines and the rate of recovery seemed 
to be inversely correlated with the growth inhibitory effect of tamoxifen. Addition 
of 0.1 pM estradiol to the D5 medium did not accelerate the initial rate of recovery 
of any of the cervical carcinoma cell lines over that obtained with D5 medium 
alone. Only MCF-7 recovered more rapidly in estradiol-containing medium than 
in D5 medium after removal of tamoxifen. When the cultures were fed simul- 
taneously with both estradiol and tamoxifen (at l/50 of the tamoxifen concentration) 
prompt recovery from tamoxifen blockade was observed only with MCF-7. The 
degree of recovery was about half that obtained when tamoxifen was removed 
and the cells were fed with estradiol. Some recovery was also noted with HeLa, 
but only after several days of feeding with both drugs. 
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DISCUSSION 
During the past decade hormone and antihormone treatment has proven to 
have a role in the therapy of malignant tumors arising from hormone-dependent 
tissues such as breast [2-51, endometrium [6,7], ovary [lo,1 11, and prostate [31]. 
Since hormonal therapy is relatively nontoxic and well-tolerated compared to 
other chemotherapeutic agents it is of interest to examine whether other malignant 
tumors are responsive to hormonal therapy as well. In recent reports the growth 
inhibitory effect of antiestrogens has been studied with cancer cells derived from 
ovary [32,33], larynx [30], other head and neck areas [34], and pancreas [351. 
The uterine cervix is a part of the hormonally regulated female genital tract, yet 
to our knowledge there have been no studies of clinical or experimental effects 
of antiestrogenic agents on cervical cancer. If effective, such treatment would 
be a valuable addition to the therapy of advanced cervical cancer. For these 
reasons and because of our findings with squamous cell carcinomas of the head 
and neck [30,34] we studied the effects of tamoxifen, a widely used nonsteroidal 
antihormone, on three cell lines derived from cancer of the uterine cervix. CaSki 
and ME-180 are well-characterized squamous carcinoma cell lines [ 15,161 and 
HeLa represents adenocarcinoma of the uterine cervix [17,28], an aggressive 
but less common histologic tumor type at this site [36,37]. As our internal control 
we used MCF-7, a breast cancer cell line which is widely used for studying the 
growth inhibitory effects and the mechanism of action of antiestrogens [19-221. 
In dose-response experiments, tamoxifen induced comparable growth inhibition 
in HeLa, ME-180, and MCF-7 at a concentration of 5 pM tamoxifen. The same 
level of growth inhibition was observed in CaSki cultures at a concentration of 
2.5 pM tamoxifen, while 5 pM tamoxifen resulted in progressive cell loss. Thus, 
at concentrations greater than 1 pM tamoxifen, CaSki cells were more sensitive 
to growth inhibitory effects of tamoxifen than were MCF-7 cells which is somewhat 
surprising. 
Results of several studies suggest that the growth inhibitory effect of antiestrogens 
is mediated through binding to estrogen receptors (ER) [19-21,381 and so the 
rationale for the clinical use of these drugs has been the presence of ER in the 
tumors. However, the clinical correlation between ER status and response to 
hormonal therapy is not complete, since 25-50% of the patients having ER+ 
breast cancer do not respond to therapy while positive responses have been 
found in lO-13% or ER- cases [39-411. Similarly, in in vitro experiments, sensitivity 
to the growth inhibitory effect of tamoxifen does not correlate directly with the 
receptor content of the tumor cells [38,42]. These observations complicate the 
interpretation of the mode of action of antiestrogens. The variations from the 
expected results could be explained either by methodological difficulties involved 
with steroid receptor assays and the variables that affect the expression of 
receptors [43] or by invoking mechanisms other than ER mediation of tamoxifen- 
induced growth inhibition. With regard to the first possibility, the subpopulation 
of MCF-7 in our use is both ER- and progesterone receptor (PgR)-positive, but 
in five different assays in two laboratories the cytosolic ER content has varied 
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from a low value of 22 to IO5 fmole/mg while PgR values have varied from 0 
to 120 fmole/mg. The variables contributing to these disparate findings appear 
to depend on the culture medium used, the phase of the growth curve, the 
density of the cells, and the laboratory that performed the receptor assay. Since 
these variables have been found to have striking effects on the receptor content 
of MCF-7, a known receptor-positive line, we are not yet certain of the receptor 
status of the cervical carcinoma lines used for this study. However, in three 
assays performed on these cells under different culture conditions, CaSki was 
negative for ER and PgR in all three, while HeLa was positive for PgR in one 
assay and ME-180 was positive for both ER and PgR in one of three assays. 
Thus, until culture conditions and assay conditions are optimized, we cannot 
rule out the possibility that the receptors are induced under certain growth 
conditions. With regard to the second possibility, several studies have demonstrated 
that cells contain antiestrogen-binding sites different from ER [38,44-461, and in 
cell growth experiments, failure of estradiol to reverse tamoxifen inhibition indicates 
that a site other than ER is important for tamoxifen-mediated growth inhibition 
in both ER+ and ER- cell lines [30,34,42]. Furthermore, Singh et al. [47] have 
demonstrated that there is a difference in the chromatin acceptor sites between 
tamoxifen-resistant and tamoxifen-sensitive MCF-7 cell lines. Thus sensitivity 
or resistance to antiestrogens may depend not only on the level of receptor, but 
also on how the occupied receptor binds to chromatin and whether the chromatin 
acceptor sites for occupied receptor are available [47]. 
In the present analysis to study further the mode of tamoxifen-induced growth 
inhibition in cervical carcinoma, the cells were exposed to cytostatic concentrations 
of tamoxifen for 3 or 4 days after which they were released by feeding them 
with tamoxifen-free medium. The growth inhibitory effect of tamoxifen was 
reversible and not due to direct toxic effects since all four cell lines started to 
grow within 24 to 48 hr after removal of tamoxifen. However, with MCF-7 only 
partial reversal of tamoxifen-induced inhibition was obtained unless estradiol was 
also added. Furthermore, simultaneous use of estradiol and a cytostatic con- 
centration of tamoxifen resulted in partial recovery from tamoxifen blockade 
only in MCF-7 cultures, indicating that there was little or no competitive binding 
between estradiol and tamoxifen in the cervical carcinoma cultures. This observation 
suggests that there are differences both in the binding site (i.e., estrogen-reversible 
or estrogen-nonreversible) and in the mechanism of growth inhibitory effect of 
tamoxifen in cervical carcinoma cell lines and MCF-7. The mechanism by which 
tamoxifen exerts its growth inhibitory effects is unknown. Nevertheless, it is 
clear that these effects can occur even in the absence of detectable levels of 
estrogen receptor and that the effect is a reversible one. 
In conclusion, we have shown that three carcinoma cell lines representing 
both squamous cell and adenocarcinoma of the uterine cervix exhibit antiestrogen- 
induced growth inhibition, which is reversible and comparable to growth inhibition 
achieved in MCF-7 cultures, but seems to be independent of the estrogen receptor. 
These results encourage us to continue preclinical studies to clarify the possible 
therapeutic value of antiestrogen therapy in the treatment of cervical cancer. 
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